Clinical Trial: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07295496) titled 'A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011' on Nov. 24.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)

Study Start Date: Dec. 08

Study Type: INTERVENTIONAL

Condition: Acute Gout Flare

Intervention: DRUG: IBI3011

* Anti-IL-RAP humanised monoclonal antibody injection

* 300 mg (2.0 mL)/vial

* Administered in accordance with the study protocol

* Single administration only

DRUG: IBI3011 Placeb...